Market LIVE
Published markets; coverage varies by country
Product profile · United States

ATROPINE SULFATE

 ·  Patent Litigation & Settlement History ↓

IngredientATROPINE SULFATE
Application typeNDA
Application213581
Product001
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
Strength1%
Approval date2022-03-15
Marketing statusPrescription
Status event—
ApplicantBAUSCH AND LOMB INC
Product source

Current GenericRadar decision

Year2022
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeAPPROVAL_DATE
Anchor date2022-03-15
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

APPROVAL_YEAR_FALLBACK: current product-specific evidence does not establish a DS/DS-equivalent or all-indication exclusivity anchor. Evidence limits: complete comparison of unverified ANDA candidates against original RLD documents remains incomplete; absence of generics is not established; complete historical patent/exclusivity collection remains incomplete.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
215624 / 001FINAL_APPROVAL · FINAL_APPROVED2021-11-26—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214752 / 001FINAL_APPROVAL · FINAL_APPROVED2022-07-14—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218148 / 001FINAL_APPROVAL · FINAL_APPROVED2024-01-08—MANKIND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217791 / 001FINAL_APPROVAL · FINAL_APPROVED2024-04-29—SOMERSET THERAPEUTICS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215618 / 001FINAL_APPROVAL · FINAL_APPROVED2024-07-01—SOMERSET THERAPEUTICS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219013 / 001FINAL_APPROVAL · FINAL_APPROVED2026-04-15—EDENBRIDGE PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219996 / 001FINAL_APPROVAL · FINAL_APPROVED2026-07-31—GLAND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 7 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
215624 / 001APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2021-11-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214752 / 001AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2022-07-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218148 / 001MANKIND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2024-01-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217791 / 001SOMERSET THERAPEUTICS LLCFINAL_APPROVAL · FINAL_APPROVED2024-04-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215618 / 001SOMERSET THERAPEUTICS LLCFINAL_APPROVAL · FINAL_APPROVED2024-07-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219013 / 001EDENBRIDGE PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2026-04-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219996 / 001GLAND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-07-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.